
STATUS UPDATE:

- (A) APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY**
 - (B) ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN KAO KUN**
 - (C) UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA**
-

1. INTRODUCTION

- 1.1. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in:
- (a) the announcements of OUE Lippo Healthcare Limited (the "**Company**") between 3 May 2016 to 30 July 2019, in relation to, *inter alia*, the appointment of receivers over certain subsidiaries of the Company¹;
 - (b) the announcements of the Company between 13 December 2017 and 30 July 2019 in relation to the arbitration and enforcement proceedings against David Lin Kao Kun ("**David Lin**")²; and
 - (c) the announcements of the Company between 22 February 2017 to 30 July 2019 in relation to on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) ("**Weixin**")³.

¹ Please refer to the Company's announcements dated 3 May 2016, 6 May 2016, 8 July 2016, 8 August 2016, 15 August 2016, 16 September 2016, 13 October 2016, 21 October 2016, 14 November 2016, 24 November 2016, 15 December 2016, 13 January 2017, 11 March 2017, 29 April 2017, 17 May 2017, 16 June 2017, 29 June 2017, 13 July 2017, 22 August 2017, 28 September 2017, 25 October 2017, 22 November 2017, 28 December 2017, 24 January 2018, 28 February 2018, 27 March 2018, 30 April 2018, 28 May 2018, 26 June 2018, 2 July 2018, 26 July 2018, 27 August 2018, 27 September 2018, 29 October 2018, 30 November 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019 and 30 July 2019.

² Please refer to the Company's announcements dated 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019, 29 April 2019, 31 May 2019, 26 June 2019, 28 June 2019 and 30 July 2019.

³ Please refer to the Company's announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019 and 30 July 2019.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

2. APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY

2.1. High Court Suit No. 441 of 2016 and High Court Suit No. 856 of 2016

Suit No. 441 of 2016 relates to, amongst others, proceedings against Fan Kow Hin for breach of his duties owed to the Company and/or unlawful conspiracy with Andrew Aathar and/or the Crest Entities in relation to the Standby Facility. Suit No. 856 of 2016 relates to the Crest Entities' claim against the Company in respect of the Standby Facility.

As announced previously on 28 June 2019, High Court Suit No. 441 of 2016 was fixed for trial on 2 to 5, 9 to 12, and 23 to 26 July 2019, and 13 to 16 August 2019. Additional hearing dates for High Court Suit No. 441 of 2016 was fixed for 20 to 23 August 2019. The trial of Suit No. 441 of 2016 concluded on 23 August 2019. The High Court will issue its judgment after closing submissions.

On 3 July 2019, the Crest Entities discontinued High Court Suit No. 856 of 2016, with costs to be paid by the Crest Entities to the Company (the "**Discontinuance**"). Notwithstanding the Discontinuance, the orders granted by the High Court on 20 October 2016 (the "**Oct16 Order of Court**") in HC/SUM 4014/2016 as part of Suit No. 856 of 2016 remain in force as the High Court had made mirroring orders in Suit No. 441 of 2016, in order to maintain the effect of the Oct16 Order of Court. Please refer to the Company's announcement dated 21 October 2016 for details of the Oct16 Order of Court.

- 2.2. There are no material updates on Aathar's Voluntary Arrangement and the other proceedings with the Crest Entities.

3. ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN

There are no other material updates for the arbitration and enforcement proceedings against David Lin.

4. VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA

4.1 Proceedings commenced by Weixin

As announced previously on 23 August 2018, Weixin commenced legal proceedings against Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) ("**Wuxi Yilin Real Estate**") and Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) ("**Wuxi Co.**"), to seek a declaration that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015 is void, and an order for the return of the land from Wuxi Yilin Real Estate to Wuxi Co.

As announced previously on 31 May 2019, a hearing was scheduled before the Wuxi Xinwu District Court on 17 May 2019 to go through the substantive trial steps. Parties

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

are waiting for the judgment of first instance to be rendered by the Wuxi Xinwu District Court.

On 8 August 2019, parties attended a further hearing for the Wuxi Xinwu District Court to consider the new evidence submitted by Wuxi Yilin Real Estate, as well as the materials retrieved by the Wuxi Xinwu District Court. The Court has not fixed any further hearings, and parties are waiting for the Court to issue a judgment for this matter. Save for the foregoing, there are no other material updates on the various litigation proceedings in the People's Republic of China.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalyst Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
30 August 2019

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com